The hypercalcaemia workup calculator assists in the systematic evaluation of elevated serum calcium, starting with albumin-corrected calcium to determine the true extent of hypercalcaemia, and then guiding the differential diagnosis through the two major aetiological categories: PTH-mediated and non-PTH-mediated hypercalcaemia. Calcium circulates in three fractions: ionised (free, biologically active, approximately 50%); protein-bound (mainly to albumin, approximately 40%); and complexed to anions (approximately 10%). Standard total calcium measurements include protein-bound calcium, meaning hypoalbuminaemia causes total calcium to appear falsely low while ionised calcium (the biologically important fraction) may be normal or elevated. The Payne correction formula corrects for this: Corrected Ca (mmol/L) = Measured Ca + 0.02 x (40 - Albumin in g/L). True hypercalcaemia (corrected Ca above 2.65 mmol/L) must then be categorised. PTH-mediated hypercalcaemia (elevated or inappropriately normal PTH despite high calcium) includes primary hyperparathyroidism (the most common cause in ambulatory patients, usually from a benign adenoma) and familial hypocalciuric hypercalcaemia (FHH, a benign inherited condition distinguishable by very low urinary calcium-to-creatinine clearance ratio below 0.01). Non-PTH-mediated hypercalcaemia (low or suppressed PTH) includes malignancy (bone metastases, PTHrP secretion, multiple myeloma), vitamin D toxicity or excess, granulomatous diseases (sarcoidosis, tuberculosis, fungal infection), thyrotoxicosis, and milk-alkali syndrome. PTH measurement is thus the pivotal branch point in the workup.
Corrected Calcium (mmol/L) = Measured total calcium (mmol/L) + 0.02 x (40 - Albumin g/L); or in mg/dL: Corrected Ca (mg/dL) = Measured Ca (mg/dL) + 0.8 x (4.0 - Albumin g/dL)
- 1Measure total serum calcium and albumin from the same blood sample.
- 2Apply the correction formula: Corrected Ca = Measured Ca + 0.02 x (40 - Albumin g/L). Normal corrected calcium: 2.20-2.65 mmol/L (8.8-10.6 mg/dL).
- 3Confirm true hypercalcaemia: corrected calcium above 2.65 mmol/L. If uncertainty remains, measure ionised calcium directly (gold standard; normal 1.15-1.35 mmol/L).
- 4Measure intact PTH (iPTH): elevated or inappropriately high-normal PTH despite high calcium suggests PTH-mediated hypercalcaemia; suppressed PTH (below 1.5 pmol/L) suggests non-PTH-mediated.
- 5For PTH-mediated hypercalcaemia: measure 24-hour urine calcium and urine creatinine. Calculate urine calcium-to-creatinine clearance ratio (UCCR). UCCR below 0.01 suggests FHH (benign, no surgery needed); UCCR above 0.01 with high PTH suggests primary hyperparathyroidism.
- 6For non-PTH-mediated hypercalcaemia: order PTHrP (malignancy), 25-OH vitamin D and 1,25-(OH)2 vitamin D (vitamin D toxicity, granulomatous disease), protein electrophoresis and Bence-Jones protein (myeloma), ACE level and CXR (sarcoidosis), TFTs (thyrotoxicosis).
- 7Assess severity and treat: mild (Ca 2.65-2.9 mmol/L) — monitor; moderate (2.9-3.4 mmol/L) — investigate and treat underlying cause; severe (above 3.4 mmol/L or symptomatic) — emergency IV fluid resuscitation, bisphosphonates, calcitonin.
Total Ca appeared only mildly elevated; corrected Ca reveals moderate hypercalcaemia requiring workup
Low albumin causes total calcium to underestimate the true calcium level. In this patient with nephrotic syndrome, the corrected calcium of 3.05 mmol/L represents moderate hypercalcaemia requiring urgent investigation (PTH, PTHrP, 25-OH vitamin D, protein electrophoresis).
Most common cause of hypercalcaemia in ambulatory patients; usually parathyroid adenoma
High calcium with high (or inappropriately non-suppressed) PTH is the hallmark of primary hyperparathyroidism. UCCR above 0.01 distinguishes it from FHH. Parathyroid adenoma is the cause in 80-85% of cases. Parathyroidectomy is curative and indicated according to the Fourth International Workshop criteria (age below 50, Ca above 2.85 mmol/L, osteoporosis, kidney disease).
Severe hypercalcaemia — emergency IV hydration + zoledronic acid; treat underlying malignancy
Humoral hypercalcaemia of malignancy (HHM) from PTHrP secretion is the most common cause of severe hypercalcaemia in hospitalised patients. PTHrP activates PTH receptors in bone and kidney, causing calcium release and reduced renal calcium excretion. Treatment of the underlying malignancy is the only definitive treatment; zoledronic acid provides effective short-term calcium control.
Sarcoid macrophages hydroxylate 25-OH vitamin D to 1,25-(OH)2 vitamin D autonomously
In granulomatous diseases (sarcoidosis, tuberculosis, berylliosis, fungal infection), activated macrophages express 1-alpha-hydroxylase, converting 25-OH vitamin D to calcitriol (1,25-dihydroxyvitamin D) independently of PTH regulation. This causes elevated calcitriol, increased intestinal calcium absorption, and hypercalcaemia. Corticosteroids are effective treatment as they inhibit macrophage 1-alpha-hydroxylase activity.
Professionals in finance and lending use Hypercalcaemia Workup as part of their standard analytical workflow to verify calculations, reduce arithmetic errors, and produce consistent results that can be documented, audited, and shared with colleagues, clients, or regulatory bodies for compliance purposes.
University professors and instructors incorporate Hypercalcaemia Workup into course materials, homework assignments, and exam preparation resources, allowing students to check manual calculations, build intuition about input-output relationships, and focus on conceptual understanding rather than arithmetic.
Consultants and advisors use Hypercalcaemia Workup to quickly model different scenarios during client meetings, enabling real-time exploration of what-if questions that would otherwise require returning to the office for detailed spreadsheet-based analysis and reporting.
Individual users rely on Hypercalcaemia Workup for personal planning decisions — comparing options, verifying quotes received from service providers, checking third-party calculations, and building confidence that the numbers behind an important decision have been computed correctly and consistently.
Extreme input values
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hypercalculatoraemia workup calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Assumption violations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hypercalculatoraemia workup calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Rounding and precision effects
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hypercalculatoraemia workup calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
| PTH Level | Diagnosis | Key Distinguishing Test |
|---|---|---|
| Elevated or high-normal | Primary hyperparathyroidism | UCCR >0.01; parathyroid scan |
| Elevated or high-normal | Familial hypocalciuric hypercalcaemia (FHH) | UCCR <0.01; family history; CaSR mutation |
| Elevated | Tertiary hyperparathyroidism (renal failure) | eGFR severely reduced; CKD history |
| Suppressed (<1.5 pmol/L) | Malignancy (HHM) | PTHrP elevated; tumour identified |
| Suppressed | Bone metastases / myeloma | XR/CT/MRI; SPEP; BJ protein |
| Suppressed | Vitamin D toxicity | 25-OH VitD very elevated; supplement history |
| Suppressed | Granulomatous disease (sarcoid, TB) | 1,25-OH2D elevated; ACE; CXR/CT |
| Suppressed | Thyrotoxicosis | TSH suppressed; FT4/FT3 elevated |
| Suppressed | Milk-alkali syndrome | History of high calcium + alkali intake; metabolic alkalosis |
When should ionised calcium be measured instead of total calcium?
Ionised (free) calcium should be measured when albumin or protein levels are significantly abnormal, in acid-base disturbances (acidosis increases ionised Ca; alkalosis decreases it), in critically ill patients (where albumin is often low), in pregnancy (albumin falls in third trimester), and when clinical symptoms of hypercalcaemia are present despite normal total calcium. Ionised calcium is the gold standard for assessing true calcium status.
What is familial hypocalciuric hypercalcaemia?
FHH is an autosomal dominant condition caused by loss-of-function mutations in the calcium-sensing receptor (CaSR) gene. The defective receptor requires a higher calcium concentration to suppress PTH, resulting in mild hypercalcaemia with high-normal or mildly elevated PTH and very low urinary calcium excretion (UCCR below 0.01 — the calcium-sensing receptor defect reduces renal calcium excretion). FHH is benign, does not cause end-organ damage, and parathyroid surgery is ineffective and contraindicated. It is the most important differential for primary hyperparathyroidism.
What are the symptoms of hypercalcaemia?
The classic mnemonic is 'bones, moans, stones, and groans': bones (bone pain, fragility fractures), moans (depression, cognitive impairment, lethargy, psychosis), stones (nephrolithiasis, nephrocalcinosis), and groans (nausea, vomiting, constipation, anorexia). Cardiac effects include shortened QT interval, bradycardia, and at very high levels (above 4.0 mmol/L) potentially fatal arrhythmias. Polyuria and polydipsia are common. Mild hypercalcaemia (2.65-2.9 mmol/L) may be entirely asymptomatic.
How is severe hypercalcaemia treated acutely?
Acute severe hypercalcaemia (above 3.4 mmol/L or symptomatic) requires: (1) IV fluid resuscitation (0.9% normal saline 200-500 mL/h to restore intravascular volume and promote renal calcium excretion); (2) intravenous bisphosphonate (zoledronic acid 4 mg over 15-30 min or pamidronate 60-90 mg over 2-4h) — onset 2-4 days, maximum effect 7-10 days; (3) calcitonin 4 IU/kg SC or IM 12-hourly for rapid initial calcium lowering (onset hours but tachyphylaxis after 48-72h); and (4) treat the underlying cause.
What is the calcium-sensing receptor and why is it important?
The calcium-sensing receptor (CaSR) is a G protein-coupled receptor expressed on parathyroid cells and renal tubular cells that monitors circulating ionised calcium. When calcium rises, CaSR activation suppresses PTH secretion and increases renal calcium excretion. Loss-of-function mutations cause FHH; gain-of-function mutations cause autosomal dominant hypocalcaemia. CaSR is the target of calcimimetic drugs (cinacalcet) used to treat secondary and primary hyperparathyroidism.
Can vitamin D supplementation cause hypercalcaemia?
Vitamin D toxicity causing hypercalcaemia requires sustained supplementation well above therapeutic doses — typically above 50,000-100,000 IU/day for weeks to months in adults with normal vitamin D metabolism. Therapeutic supplementation of 800-4000 IU/day is very unlikely to cause hypercalcaemia. However, patients with granulomatous diseases (sarcoidosis) or Williams syndrome are exquisitely sensitive and can develop hypercalcaemia at low supplementation doses.
What blood tests should always be ordered in hypercalcaemia workup?
First-line workup: corrected calcium, albumin, ionised calcium if available, intact PTH, phosphate, alkaline phosphatase, eGFR, and urinalysis. If PTH is suppressed: PTHrP, 25-OH vitamin D, 1,25-(OH)2 vitamin D, serum protein electrophoresis, serum free light chains, ACE level, and TSH. If PTH is elevated or high-normal: 24-hour urine calcium and urine creatinine for UCCR calculation.
When is parathyroid surgery indicated in primary hyperparathyroidism?
The Fourth International Workshop on Asymptomatic Primary Hyperparathyroidism (2014) recommends parathyroidectomy in: age below 50 years; serum calcium more than 0.25 mmol/L above the upper limit of normal; eGFR below 60 mL/min/1.73m2; T-score below -2.5 at any site or vertebral fracture; 24-hour urine calcium above 10 mmol/day with nephrolithiasis risk factors; and markedly elevated urinary calcium excretion. Patients not meeting surgical criteria require annual monitoring.
Pro Tip
A useful rapid assessment: in any hospitalised patient with unexplained hypercalcaemia and suppressed PTH, the two most important diagnoses to exclude urgently are malignancy (PTHrP, protein electrophoresis) and sarcoidosis (1,25-OH2D, ACE, CXR). Ordering these alongside the corrected calcium and PTH at the first workup avoids diagnostic delays.
Did you know?
The parathyroid glands were the last of the major endocrine glands to be discovered — by Swedish medical student Ivar Sandstrom in 1880. They are notoriously variable in number (usually 4, but ranging from 2 to 6 or more) and location, which makes parathyroid surgery technically challenging. A single adenoma weighing less than a grain of rice can be responsible for significant hypercalcaemia and its life-limiting complications.
References
- ›Bilezikian JP et al. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism (4th International Workshop 2014). J Clin Endocrinol Metab 2014
- ›Shane E, Dinaz I. Hypercalcemia: Pathogenesis, Clinical Manifestations, Differential Diagnosis, and Management. In: Primer on the Metabolic Bone Diseases 2013
- ›Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician 2003
- ›NICE CKS — Hypercalcaemia 2022
- ›Stewart AF. Clinical practice — hypercalcemia associated with cancer. NEJM 2005